|
Release Date
December 10, 2010
|
Expiration Date
December 10, 2011 |
|
|
| Faculty |
Harold Burstein, MD, PhD
Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
William J. Gradishar, MD, FACP
Northwestern University
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States
|
Clifford Hudis, MD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
Kathy Miller, MD
Indiana University
Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
|
|
Antonio Llombart Cussac, MD, PhD
Hospital Universitario Arnau de Vilanova
Lleida, Spain
|
Hyman Muss, MD
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
|
Edith Perez, MD
Mayo Clinic
Jacksonville, Florida, United States
|
|
|
|
|
|
|
Target Audience
This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, pathologists, radiologists, and other healthcare providers involved and/or interested in the care of patients with breast cancer.
|
Overview
These interviews are regarding recently released data from the 2010 CTRC-AACR San Antonio Breast Cancer Symposium, focusing on various aspects of the management of patients with breast cancer. |
Educational Objectives
Upon completion of this educational activity, participants should be able to:
- Evaluate genomic and proteomic tools for the assessment of recurrence risk, prediction of benefit from chemotherapy, and individualization of therapeutic decision making, while identifying the latest and most important prognostic and predictive factors in breast cancer
- Summarize current therapeutic options for the management of patients with early-stage or locally advanced breast cancer
- Evaluate the use of emerging strategies for targeting HER2 in early breast cancer, focusing on the rationale, mechanism of action, patient selection, and safety profile of novel agents and regimens in HER2-positive breast cancer
- List the most promising current and future strategies for the management of metastatic breast cancer
- Interpret and integrate recent clinical trial data into improved patient management strategies
|
Sponsorship Statement
This activity is sponsored by prIME Oncology. |
Accreditation Statement
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. |
Credit Designation Statement
prIME Oncology designates this enduring Internet-based educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Each interview may provide the following credits:
- Endocrine-Responsive Breast Cancer [Gradishar/Muss: 2010591-1]: 0.25 CME credits
- Early HER2-Positive Breast Cancer [Gradishar/Perez: 2010591-2]: 0.25 CME credits
- Early Breast Cancer [Gradishar/Hudis: 2010591-3]: 0.25 CME credits
- Prognostic/Predictive Tools for Breast Cancer [Gradishar/Burstein: 2010591-4]: 0.25 CME credits
- Advanced Breast Cancer [Gradishar/Miller/Llombart: 2010591-5]: 0.25 CME credits
|
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be e-mailed to you.
Links to the post-tests are available on the activity selection page and video player pages.
|
Technical Requirements
To participate in this activity, your computer should have a processor the equivalent of Intel Pentium II 450 MHz or faster, with 128MB of RAM and a connection to the Internet.
Estimated time to complete activity: 1.25 hours
|
Support Statement
This educational activity is supported by AstraZeneca; Genentech; Genomic Health, Inc.; and Novartis Pharmaceuticals Corporation. |
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support, educational activities sponsored by prIME Oncology must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in a prIME Oncology–sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Dr Burstein has disclosed that he or his spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Dr Gradishar has disclosed that he or his spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Dr Hudis has disclosed that he has received consulting fees from Genentech and F. Hoffman-La Roche, Ltd. He has also performed contracted research for Merck & Co., Inc., and Onyx Pharmaceuticals. None of these relationships will impact his ability to present an unbiased discussion.
Dr Llombart has disclosed that he or his spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Dr Miller has disclosed that she has received consulting fees from MethylGene Inc. She has received fees from non-CME services from Genentech. She has also performed contracted research for Amgen Inc; Genentech; Geron; Merrimack Pharmaceuticals; Pfizer Inc; and Syndax Pharmaceuticals, Inc. None of these relationships will impact her ability to present an unbiased discussion.
Dr Muss has disclosed that he has received consulting fees from Abraxis BioScience; Amgen Inc; Boehringer-Ingelheim Pharmaceuticals, Inc; Bristol-Myers Squibb Company; Eisai Inc; F. Hoffmann-La Roche, Ltd.; Sandoz; and Wyeth/Pfizer Inc. None of these relationships will impact his ability to present an unbiased discussion.
Dr Perez has disclosed that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The employees of prIME Oncology have disclosed:
- Michael Checkoway (project management) – no real or apparent conflicts of interest
- Amy Furedy, RN, OCN (clinical) – no real or apparent conflicts of interest
- Trudy Stoddert, ELS (editorial) – no real or apparent conflicts of interest
- Heather Tomlinson, MA (editorial) – no real or apparent conflicts of interest
- Susan H. Yarbrough, CCMEP (compliance) – no real or apparent conflicts of interest
|
Disclosure of Unlabeled Use
This educational activity may contain discussion of published or and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. prIME Oncology and the supporters of this activity do not recommend the use of any agent outside of the labeled indications. |
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|
